Home » ISPOR Posters » Extrapolation of Time-To-Event Data in Various Disease Areas: Current Recommendations and Gaps

× Share this Article

Extrapolation of Time-To-Event Data in Various Disease Areas: Current Recommendations and Gaps

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

What EU Means to the MHRA: Potential Impact of 'Brexit' on Pharmaceutical Regulation in the UK

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

Estimating the Value of a New Antibiotic: A Novel Approach Using ESBL as a Case Study

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

Most Recent Articles

Implications Of Brexit On European Pharmaceutical Market Access

NITAG Hears A WHO!

Orphan Legislation - Left No One Behind?

A Comparison Of Individual Patient Data (IPD) Regression Techniques In Adjusting For Cross-Trial Differences...

Global Growth In Public Healthcare: Emerging Markets Take The Wheel

Biosimilar Market Access: Comparing The US and European Markets

Emerging Privates: Identifying The Major Markets For Private Healthcare Expenditure

A Foot In The Door Or One Foot In The Grave? The Role Of Real World Evidence In Cancer Drugs Fund Re-Appraisals

Squaring The Circle? Using Real World Data From Early Access Programs To Inform Pricing And Reimbursement Decision Making

Nice-ly Paving The Way? Dynamic Pricing: The Future Of Reimbursement

Navigating Real World Evidence In Oncology: Where To Go And Why

Combating Rising Obesity in AMCP Dossiers? The New AMCP Dossier Format - Version 4.0

Commercializing Regenerative Medicines in the US - What Lessons Can We Learn From Europe?

ICER Reports - 4 Years of Cost/QALY Drug Evaluations in the USA...What Does the Future Hold?

Mission Possible? Demonstrating Robust Cost-Effectiveness Without Any Comparative Phase III Data

The Elephant(s) in the Room: Aggrandizement of STA Guidance Workload For Nice

Are FDA Accelerated Approvals Unconditional Approvals?

Is Eunethta Enough? The Remaining Challenges in Navigating the Early European Regulatory and HTA Advice

FDA Orphan Exploitation? Are Pharma's Approaches to Orphan Oncology Drug Approvals Fuelling A Push for Reform by the FDA?

The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review